Skip Navigation

Division of AIDS (DAIDS)

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

HIV/AIDS Clinical Trials Networks

The NIAID HIV/AIDS Clinical Trials Networks have been designed to address NIAID’s five HIV/AIDS scientific priorities:

  1. Therapeutics for HIV/AIDS and HIV-associated infections in adults (including HIV cure, as well as co-occurring noninfectious and infectious diseases, including hepatitis and tuberculosis) (ACTG)
  2. HIV/AIDS and HIV-associated infections in children and mothers (IMPAACT)
  3. Integrated strategies to prevent HIV infection (HPTN)
  4. Vaccines to prevent HIV infection (HVTN)
  5. Microbicides to prevent HIV infection (MTN)

AIDS Clinical Trials Group (ACTG)

  • Principal Investigator: Daniel R. Kuritzkes, M.D.; Brigham and Women’s Hospital, Boston

HIV Prevention Trials Network (HPTN)

  • Principal Investigator: Wafaa El-Sadr, M.D., M.P.H., and Myron Cohen, M.D.; FHI 360, Durham, North Carolina

HIV Vaccine Trials Network (HVTN)

  • Principal Investigator: Lawrence Corey, M.D., Glenda Gray, M.B.B.Ch., and Scott Hammer, M.D.; The Fred Hutchinson Cancer Research Center, Seattle

International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)

  • Principal Investigator: Jay Brooks Jackson, M.D.; Johns Hopkins University School of Medicine, Baltimore

International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)

  • Principal Investigator: James D. Neaton, Ph.D.

Microbicide Trials Network (MTN)

  • Principal Investigator: Sharon L. Hillier, Ph.D., and Ian Michael McGowan, M.D., Ph.D.; Magee-Womens Research Institute and Foundation, Pittsburgh

back to top

Last Updated April 04, 2014

Last Reviewed August 11, 2010